Call for papers - Reproduction, Technology and Society, a new section in Reproductive BioMedicine Online
Page URL:

Genomics England and Illumina partner on whole genome sequencing

20 January 2020
Appeared in BioNews 1031

Genomics England has announced it will partner with Illumina, a US-based manufacturing and service company providing automated DNA sequencing, to sequence up to 300,000 whole genomes over the next five years, with an option to increase the number to 500,000.

The partnership builds on the 100,000 Genomes Project, which was successfully completed by Genomics England in partnership with Illumina in December 2018. Genomics England was specifically founded by the UK Department of Health and Social Care to run the 100,000 Genomes Project. The project previously established protocols for consent from patients with rare genetic diseases and cancer, tissue sample requirements, standardised DNA sequencing, data analysis and reporting.

The new collaboration is set to analyse further samples from NHS patients with rare diseases to support diagnosis and improve treatment options. The clinical samples will be provided through the NHS Genomic Medicine Service. It is expected that the number of diseases eligible for sequencing will expand over time. Additionally, Genomics England will provide sequencing samples for research purposes.

The project also supports the ambition voiced by health secretary Matt Hancock to analyse up to five million genomes by 2024 in the hopes of the UK maintaining its position as a global leader in the field of genomics.

'The introduction of whole genome sequencing as part of routine clinical care...represents a step change in the genomic testing available on the NHS' said Professor Sue Hill, chief scientific officer for NHS England. She continued: 'This will enhance our ability to fully embrace all aspects of personalised medicine from predictive prevention to more precise diagnosis and targeted treatment for better outcomes.'

Sequencing will be undertaken by Illumina Laboratory Services in Cambridge, UK. In October 2019 is was announced that UK Research and Innovation would allocate £200 million to sequence 500,000 human genomes to better understand, treat and prevent severe diseases, such as cancer and dementia.

Dr David Bentley, chief scientist at Illumina said: 'Building on the highly innovative and successful 100,000 Genomes Project, we're delighted to move to the next phase of working with Genomics England, and now also with the NHS, to help transform England's healthcare service into the first in the world to benefit from routine whole genome sequencing.'

The sequencing service is expected to start in April of this year. Illumina said it will not store any patient samples or data.

Genomics England and Illumina partner to deliver whole genome sequencing for England’s NHS Genomic Medicine Service
Genomics England |  13 January 2020
Genomics England, Illumina join forces on whole genome sequencing
Pharma Times |  14 January 2020
Illumina, Genomics England Ink Deal to Sequence up to 300K People
Genome web |  14 January 2020
4 May 2020 - by Dr Joanne Delange 
Baroness Nicola Blackwood has been appointed chair of Genomics England...
13 January 2020 - by Charlott Repschlager 
A new form of DNA testing that has the potential to rapidly diagnose rare diseases in critically ill babies and children has been made available on the NHS...
4 November 2019 - by Rikita Patel 
New genetic variants found in an African population provide insights into human health, according to a large genome study...
9 September 2019 - by Eleanor Taylor 
The Progress Educational Trust (PET), which publishes BioNews, held a public event at Manchester's Science and Industry Museum to discuss genomics...
29 July 2019 - by Rachel Siden 
A new report has called for genome sequencing to be trialled alongside the nine tests that currently comprise newborn screening in the UK...
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.